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Genetic testingRecent advances in sequencing technology are making possible the application of large-scale genomic analyses
to individualized care, both in wellness and disease. However, a number of obstacles remain before genomic se-
quencing can become a routine part of clinical practice. One of the more signiﬁcant and underappreciated is the
lack of consensus regarding the proper environment and regulatory structure under which clinical genome se-
quencing and interpretation should be performed. The continued reliance on pure research vs. pure clinical
models leads to problems for both research participants and patients in an era in which the lines between re-
search and clinical practice are becoming increasingly blurred. Here, we discuss some of the ethical, regulatory
and practical considerations that are emerging in the ﬁeld of genomic medicine. We also propose that many of
the cost and safety issues we are facing can be mitigated through expanded reliance on existing clinical regula-
tory frameworks and the implementation of distributive work-sharing strategies designed to leverage the
strengths of our genomics centers and clinical interpretive teams.
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We are entering a fascinating and uncertain period of medical histo-
ry, as today's DNA sequencing technology has the potential to help each
of us direct our care and predict our future based on knowledge of our
own individual inherited and acquired genetics. However, from a global
and local economic perspective, these are lean years, and this adds a sig-
niﬁcant degree of uncertainty to the immediate future of this enterprise.
It is therefore incumbent upon us to show that the personalizedmedicalpen access article under the CC BY-NC-ND license
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burdensome cost center, but that it truly has the potential to save both
lives and health care expenses via data-driven management, early dis-
ease detection/screening andmore efﬁcacious pharmaceutical delivery.
To this end, we need to determine how to move forward towards ex-
panded clinical use of this technology in a manner both rapid and eco-
nomical, while ensuring the integrity of the process and the safety and
well-being of patients and research participants. This will require care-
ful thought and consideration regarding the proper environment and
regulatory structure surrounding genomics, as well as the development
of consensus regardingwhat exactly constitutes a genetic test in the age
of large-scale genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease” must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
Research laboratories performing investigative analyses of human
samples that are not meant to provide clinically actionable results
are currently considered exempt, and it is a simple fact that most re-
search laboratories do not have sufﬁcient standards in place to qualify
them for CLIA approval (Lyon, 2012a,b). At the time CLIA was enacted,
the separation of the clinical and research worlds seemed a fairly
straightforward proposition. But today, the issues we face from a reg-
ulatory and ethical standpoint around genomics stem from the simple
question: what do we do when it becomes difﬁcult to draw a clear
line of distinction between these two types of laboratory practices,
particularly when researchers are working directly with families?
Next generation sequencing (NGS) technology has fundamentally
transformed what it means to perform research on human partici-
pants, as a direct consequence of its power, speed and efﬁcacy
(Lyon and Wang, 2012). Rare disease discovery research is nothing
new: we have been analyzing samples from rare disorders in a scien-
tiﬁc, hypothesis-driven way for more than a century. What has
changed are the prospects for meaningful ﬁndings in a clinically ac-
tionable time frame, as well as the relative standardization of these
research practices. Families afﬂicted with rare genetic disorders now
have a reasonable expectation of deﬁnitive and potentially actionable
results on the order of weeks to months, and all such families regard-
less of diagnosis are candidates for a relatively standardized genomic
(rather than disease-speciﬁc mechanistic) analysis. The situation is
similar for cancer patients, as standardized tumor-agnostic genomic
analyses have a high likelihood of uncovering plausible drug targets
during the lifetimes of patients, even those with late-stage disease.
The impact of altered expectations and standardized methods
should not be underappreciated. Most critically, the implementation
of NGS has resulted in a rapid evolution of research practices towards
a process whereby suitable patients (usually with either cancer or a
rare genetic disease) are referred by clinicians into exome (Ng et al.,
2008, 2009, 2010a, 2010b; Musunuru et al., 2010; Choi et al., 2009;
Albert et al., 2007; Hodges et al., 2007; Okou et al., 2007; Need et al.,2012) orwhole genome sequencing (WGS) (Lam et al., 2012) research
programs. However, rather than being driven mainly by a hypothesis-
driven basic discovery motive, the goal is increasingly patient-focused
and intended to ﬁnd information of clinical beneﬁt to the participant,
indeed blurring the lines between “patient” and “research partici-
pant”. Perhaps the key difference is ultimately with intent, but as the
shift is made from basic discovery to participant-focused analysis, it
becomes necessary to admit that, for these participants, the process
is becoming a clinical one. Underscoring this trend is the release of a
growing number of CLIA-certiﬁed exome sequencing tests at some of
the larger genetics laboratories, including Baylor, Ambry Genetics,
and elsewhere. However, there persists a healthy amount of disagree-
ment regarding the proper environment and regulatory framework
for human genome sequencing.
We believe that the observed shift from research to the clinic is
natural and positive, a clear sign of the growing prospects for individ-
ualized or precisionmedicine (Anon., 2011). But, at the same time, this
changing landscape begs an in-depth discussion of the ethical and reg-
ulatory issues that face genomics research and genomic medicine. Ul-
timately, the goal of such a discussion is to lead the ﬁeld towards
increased standardization, improved conﬁdence in both individual re-
sults and shared datasets, and the elimination, or at least reduction, of
redundant sequencing and conﬁrmatory re-testing. It is our belief that
we as a ﬁeld need to re-think the boundaries between clinical and re-
search practice. A recent report from the Presidential Commission for
the Study of Bioethical Issues (Anon., 2012a) acknowledged this, and
among their many recommendations we would like to highlight the
following:
Recommendation 4.1
Funders of whole genome sequencing research, relevant clinical
entities, and the commercial sector should facilitate explicit ex-
change of information between genomic researchers and clini-
cians, while maintaining robust data protection safeguards, so
that whole genome sequence and health data can be shared to ad-
vance genomic medicine.
Performing allwhole genome sequencing in CLIA-approved laborato-
ries would remove one of the barriers to data sharing. It would help
ensure that whole genome sequencing generates high-quality data
that clinicians and researchers can use to draw clinically relevant
conclusions. It would also ensure that individuals who obtain their
whole genome sequence data could share them more conﬁdently in
patient-driven research initiatives, producing more meaningful data.3. Feasibility of clinical sequencing?
Some in the ﬁeld might argue for the continued suitability of the
“research ﬁrst, clinical follow-up” model. Economics are a common
area of concern, as the average cost for a CLIA-certiﬁed exome is cur-
rently about 2–3-fold higher than the price for a typical research
exome at the same sequencing depth. As of November 2012, for
example, one company appears to be charging $7900 for a trio of
clinical grade exomes, including both parents and one child, for a
cost of ~$2600/exome (Davies, 2012). In contrast, the typical cost
for exomes in research laboratories is ~$1000–1500, depending on
many variables. There are a few main reasons for this discrepancy
between “research-grade” and “clinical-grade” sequencing, of which
some are largely matters of accounting. The largest driver of price
discrepancy between the research and clinical exomes is the hours
of professional interpretation time built into the cost of the CLIA
exome. On the research side, when a patient undergoes exome sequenc-
ing, typically the same level of interpretive effort is spent on their case,
but it is performed both by teams of researchers as a basic component
of their duties as well as by physicians on a non-billed basis. Regardless,
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ultimately reimbursed, just not via straightforward accounting.
Another cost issue is that of result conﬁrmation. Researchers are
barred by CLIA from releasing non-CLIA certiﬁed results to partici-
pants or physicians that will impact diagnosis or management. Cur-
rently when an actionable result is found, a new sample can be sent
to certain CLIA-approved laboratories specializing in the conﬁrmation
of that individual variant, at a cost of approximately $300 per variant
(Anon., 2012b). However, until recently, it was not well known by re-
searcherswhich companieswill provide such testing for new genes, as
one of us discovered and discussed in a recent commentary (Lyon,
2012b) and blog posting (Lyon, 2012a). This cost is not factored into
the research exome, but is an included and currently essential compo-
nent of all currently marketed CLIA exome offerings. Looking forward,
as we learn more and more from the genome, and depending upon
what types of data individuals want to receive from their genomes,
the number of variants requiring conﬁrmation will only increase,
perhaps substantially. At $300 per variant (which is Sanger-based
and unlikely to change anytime soon), the researchmodelmay rapidly
become prohibitively expensive when used to manage care. Eventual-
ly the technology and informatics might allow for clinical-grade conﬁ-
dence in primary next generation sequencing data such that Sanger
re-sequencing will not be required, but this could only legally be
achieved via CLIA-certiﬁed NGS.
Other signiﬁcant factors leading to higher CLIA prices are amor-
tized validation/development costs and volume-related costs. Both
of these factors reduce to issues of volume, as up-front validation
costs would diminish in signiﬁcance as volume increases. The typically
low volume of samples processed by CLIA genomics centers affects
price as well, as this either necessitates less frequent runs (with great-
er instrument depreciation per run) or under-multiplexing. For exam-
ple, a larger CLIA genomics operation may run on the order of a few
hundred clinical exomes per year, whereas a research center may se-
quence 20,000 or more with resultant economies of scale in sample
and library preparation as well as sequencing. In the subsequent sec-
tions we will discuss mechanisms for performing more sequencing
within CLIA operations, which may largely serve to obviate this
problem.
4. Beneﬁts of sequencing in CLIA-certiﬁed laboratories
Before delving into strategies for expanding the role of CLIA in ge-
nomic sequencing, it is worth exploring the potential beneﬁts that
increased oversight could produce for both clinical and research ap-
plications. There would clearly be some costs associated with expand-
ed oversight that the beneﬁts would have to outweigh. It is important
to note that CLIA accreditation is much more than just a rubber stamp
on a laboratory, and merely performing sequencing in a CLIA-certiﬁed
facility does not sufﬁciently satisfy the requirements of the CLIA stat-
utes, as we will discuss.
Prior to the enactment of CLIA, there were widespread abuses
throughout the clinical laboratory community. For example, in the
1960s in New York State, a sweeping investigation of laboratories
uncovered a startling array of deﬁciencies, including labs that were
run by untrained personnel (including insurance salesmen), labs
that routinely performed testing on spoiled specimens or used in-
adequate equipment, and labs (like one lab that reported every
pregnancy test as positive) that simply returned fraudulent results
(Dales, 1964; Godbout, 1960). We are certainly not suggesting that
today's research-grade facilities in any way compare to these
pre-CLIA labs, but we do believe that the straightforward practices
dictated by CLIA can provide signiﬁcant protections. Clearly history
has shown that the quality of unregulated diagnostics is susceptible
to perverse market forces, as all of the poor practices above can be
tied directly to economic conﬂicts of interest. At a minimum, CLIA
erects a wall protecting laboratories from these forces and providesan enforcement structure. The ﬁeld would be prudent to embrace
this protection, in light of the ongoing commoditization of sequenc-
ing (Mardis, 2011; Anon., 2010) and its associated potential for se-
vere price competition.
As part of its requirements, CLIA mandates oversight of physical
plant and stafﬁng, quality control, quality assurance and quality
improvement practices, laboratory documentation and specimen han-
dling policies, individual test validation and performance procedures,
interpretation and reporting practices, and proﬁciency testing pro-
grams. With respect to individual assays, any laboratory performing
high-complexity non-FDA approved genetic tests must perform vali-
dation studies to establish (as appropriate) accuracy, precision, ana-
lytical sensitivity, analytical speciﬁcity, reportable range, reference
intervals, and any other important performance characteristics, and
to determine and document all calibration and control procedures.
Bi-annual proﬁciency testing is mandated, involving a comparison
with another CLIA facility usingmatched specimens, which is a critical
process for uncovering outlier laboratories and un-noticed technical
issues. These are all important and straightforward controls that pro-
vide the type of assurance that anyone shouldwant before using geno-
mic information to inﬂuence healthcare choices.
Though the “research ﬁrst, clinical follow-up” model does provide
CLIA assurance for select positive ﬁndings deemed clinically signiﬁ-
cant, this model has a number of drawbacks. Most fundamentally,
the problem is not in how to handle positive results, but in how to un-
derstand and interpret negative or absent results. Without formal
validation (accuracy, expected and actual coverage details, inter-lab
validation, etc.) or clinical-grade specimen handling, an individual re-
ceiving a negative result might be overly conﬁdent in that result or be
left wondering about the laboratory or speciﬁc test factors like cover-
age, informatics, and interpretation and ultimately be left unsure
about how to proceed.
As mentioned previously, the number of clinically signiﬁcant sec-
ondary ﬁndings from research exomes or genomes will only increase
over time, and the only way to move towards a future without re-
quired Sanger conﬁrmation is in the CLIA setting. An additional prob-
lem, addressed above, is that these ﬁndings are only currently
permitted to break the research/clinical barrier if they pose a signiﬁ-
cant health risk (Wolf et al., 2012). All other information, including
but not limited to pharmacogenomics information, carrier status,
and disease risk associations is currently not returned. As the vast ma-
jority of exome and genome sequencing conducted today is per-
formed in the research setting, this represents an enormous waste of
potentially life-altering information. Moreover, the transference of
that much data to participants and the resulting personal and clinical
follow-through would be its own rich source of learning about the
real-life practice of personalized medicine. Thus, we as a population
are doubly deprived when that information remains behind the
research ﬁrewall. Primary CLIA sequencing could circumvent this
issue and potentially allow clinical analysis and use of all genomic
data frommany research projects. The ultimate goal, translating geno-
mic information into care algorithms for well individuals and families,
is a monumental challenge, and we will not get there unless we can
move towards unleashing this information in the safest and most
standardized way possible, and carefully examining and cataloging
downstream ramiﬁcations.
Another overlooked beneﬁt of performing more standardized ge-
nome sequencing would be its effect on resultant datasets, and the
community's resultant conﬁdence therein. Research genomics datasets
routinely feed into a variety of databases, such as dbSNP, DECIPHER
(Swaminathan et al., 2012), the NHLBI Exome Sequencing Project
(Norton et al., 2012), and the 1000Genomes Project (Abecasis et al.,
2012), to name just a few. These databases have become critical tools
for physicians and researchers attempting to assign clinical meaning
to variant sets. Thus, non-clinical data can have a dramatic impact on
even the most optimally validated clinical assays. However, it is well
Table 1
Processes involved in a CLIA-certiﬁed genetic test.
Preanalytic system
1) Test request and specimen collection criteria
2) Specimen submission, handling and referral procedures
3) Preanalytic systems assessment
Analytic system
1) A detailed step-by-step procedure manual
2) Test systems, equipment, instruments, reagents, materials and
supplies
3) Establishment and veriﬁcation of performance speciﬁcations
4) Maintenance and function checks
5) Calibration and calibration veriﬁcation procedures
6) Control procedures, test records, and corrective actions
7) Analytic systems assessment
Post-analytic system
1) Test report, including (among other things):
a) interpretation
b) reference ranges and normal values
2) Post-analytic systems assessment
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results and annotation, to the extent that some authors are even argu-
ing against adoption of increased clinical standards due to their
unreliability (Ledoux, 2012). We would argue that regulatory reform
will actually result in additional positive feedback, as CLIA results
would help to improve both the depth and quality of clinical variant
databases that would in turn boost our clinical interpretive power.
When viewed in this light, sequencing in CLIA-certiﬁed laboratories
could produce signiﬁcant beneﬁts for nearly any person undergoing
genome sequencing, whether for research or clinical purposes.
5. Applying CLIA to genomics
While in theory it sounds reasonable to advocate for all exome or
genome sequencing to be performed to CLIA standards, it begs the
question: wouldn't this be a practical nightmare? There are many ra-
tional worries about this model, for while the actual sequencing pro-
cesses may be, or at least could be, standardized, the informatics and
interpretive processes are often designed to be quite different, both
across centers but also across the myriad of individual clinical and
translational research projects performed by all of the various groups
and collaborators at each institution.
With respect to sequencing, while not all exomes and genomes se-
quenced would qualify (because many require modiﬁed library preps,
read lengths or read depths), the majority of constitutional exomes
and genomes run today (and a growing number of cancer exomes
and genomes) are assayed by one of a small number of standardized
library preparation and sequencing techniques. Today,mostwhole ge-
nome sequencing involves either fragmentation/ligation or Nextera-
based library preparation and 100 base paired-end 30× sequencing
(Illumina) or circularized “nanoball” preparation with 35 base paired-
end sequencing (Complete Genomics). Exome sequencing is almost
entirely performed on Illumina equipment using one of a few library
preparation methods, with 100 base paired-end sequencing performed
in the major research sequencing centers to an average depth of 70–
100× to achieve >80% of the target region covered by 20 or more
reads. Others havemade suggestions for standardizing exome sequenc-
ing (Klein et al., 2012), and we believe it is high-time to establish such
standards, at least for exomes being sequenced from live human beings,
so that results can be returned to participants.
However, while sequencing is relatively standardizable, it is true
that many of the downstream processes are not, as bioinformatics
analyses and interpretive schemes can be extremely variable. While
the desired informatics and interpretive analysis for healthy individ-
uals might focus on alleles relevant for future disease risk, carrier sta-
tus and pharmacogenomics, genomic analyses for rare diseases might
instead focus on de novo, homozygous or X-linked disease variants,
possibly in the context of a parent–child trio or preferably in the con-
text of even larger families, including grandparents. Certain ﬁndings
seen in one patient may escape detection in another patient simply
due to differences in the basic strategy of analysis or the phenotype
of the individuals. With respect to population studies, the analytical
variation can be tremendous, with focuses ranging from ethnicity-
speciﬁc variation to variation associated with complex disease, basic
human phenotypes and evolutionary processes. The number of differ-
ent performable analyses is limited only by the imagination.While the
informed consent process for each individual study would be required
to include a discussion of the analysis details, the process can be con-
fusing for participants and easily leave them at the end unclearwheth-
er or not particular ﬁndings were investigated and frustrated by an
inability to access the data. This being the case, it would be beneﬁcial
to move towards a systemwhereby a straightforward clinical analysis
of data from research projects could be subsequently performed at a
later time, within a proper regulatory framework.
This downstream variation in informatics and interpretation raises
an important question: from the clinical standpoint, what exactlyconstitutes a genetic laboratory test? Is it simply the analytics (the se-
quencing), or is it a combination of analytics and interpretation, or
is it the entire process from sample receipt through to the generation
and return of a report? Here, the legal deﬁnition is really quite
clear, as CLIA speciﬁcally states that a medical laboratory test is an all-
encompassing process (Anon., 2013a). The introduction to CLIA subpart
K states that “each laboratory that performs nonwaived testingmust es-
tablish and maintain written policies and procedures that implement
and monitor quality systems for all phases of the total testing process
(that is, preanalytic, analytic, and postanalytic) as well as general labo-
ratory systems” (see Table 1 for a summary of the analytic systems).
It is noteworthy that test interpretation and reporting are speciﬁ-
cally covered by the CLIA statutes and included as part of the regulated
test process. This is important because, as the community has discov-
ered, the actual sequencing has become increasingly straightforward,
whereas the true difﬁculties and pitfalls lie in the informatics, inter-
pretation and reporting. Any meaningful regulatory framework for
NGS-based diagnostics must include oversight of informatics path-
ways and interpretive criteria, as there are simply too many ways to
do informatics incorrectly, with resultant possibilities for harm to pa-
tients and participants.
This issue is beginning to get the attention of the agencies respon-
sible for overseeing clinical laboratories, now that a large number of
clinical laboratories have begun developing a variety of tests on NGS
instruments. The College of American Pathologists (CAP) has recently
released a new checklist for molecular pathology laboratories that
includes both general laboratory and test development guidelines
covering NGS wet lab practices, bioinformatics processing and data
storage and transfer practices. Additionally, the New York State De-
partment of Health Clinical Laboratory Evaluation Program (CLEP)
has issued detailed guidelines for the development and validation
of NGS cancer genomics assays (Anon., 2013b). New York is one of
two CLIA-exempt states as a result of its own state licensure regula-
tions being deemed “equal to, or more stringent than” CLIA by CMS
per CLIA subpart E, thus clinical laboratories in New York receive
their CLIA license through the state following successful state certiﬁ-
cation. The CLEP NGS oncology guidelines are quite thorough, includ-
ing requirements for quality scores, control procedures, acceptable
numbers of specimens for validation studies and guidelines for
establishing read depth, accuracy, sensitivity, etc., focusing on actual
performance rather than the details of bioinformatics pipelines. Over-
all, the regulatory framework for NGS on the pure clinical side is com-
ing together, with certain aspects such as reporting criteria hopefully
being sorted out in the near future.
However, if a clinical NGS test is deﬁned by both the sequencing
and downstream informatics, and the informatics possibilities for a
standard sequence are essentially limitless, how could CLIA
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operations without placing an extreme regulatory burden on the se-
quencing laboratory? Would every analysis type need to be certiﬁed,
or would a time-consuming standardized analysis be required even
if it were not needed for each particular operation?
6. The distributive model: an analytical-interpretive split
across genomics
Any ideal solution would allow sequencing centers to focus on
their strengths and to leverage their economies of scale, without re-
quiring them to devote their time to unnecessary informatics and in-
terpretation. How can that be achieved in keeping with the spirit of
proper CLIA oversight? As a solution, we would propose an analytic-
interpretive split (or a so-called “distributivemodel”) across both clin-
ical and research genomics. This split model simply means that one
laboratory performs analytics and then a second laboratory performs
the interpretation and reporting. Thus, together, the two laboratories
perform all the functions that make up a laboratory test. This should
be a straightforward arrangement, but while some precedent and
guidance policies exist, the regulatory structure that would govern
such a system is still evolving, as we will discuss.
The beneﬁts of enacting such a split model could be substantial,
and we believe they could be gained without signiﬁcantly burdening
our sequencing centers with undue excess costs. Under this type of
system, the basic sample processing and sequencing operation could
be standardized across clinical patients and the majority of new geno-
mics research participants. The practical effect of this split would be
to turn an exome or genome sequence into a discrete deliverable unit
that could be used for multiple downstream purposes by multiple
downstream labs. For each patient or participant, the same validated
sequencing would be performed, and that raw data, if individually de-
sired, could be merged with their electronic health record. Then, the
data could be directly used per consent agreement with researchers
for any type of downstream investigative analysis. It could also be
used for any type of downstream clinical analysis for guidance of
healthcare decisions. As we move towards higher-quality primary
data, depending on the type of analysis, this CLIA-certiﬁed raw data
could be interpreted and used to guide healthcare choices with less
requirements for Sanger validation, obviating the need for secondary
ﬁnding conﬁrmation and resulting in large cost savings.
In turn, we believe the resources required to install CLIA oversight
of genomics centers would not be prohibitive. Genomics labs would
need to hire personnel and set up the physical plant commensurate
with CLIA and state regulations. Most genomics centers, being rela-
tively new andwell equipped, would not require major modiﬁcations.
In terms of test development, a modest number of assays and conﬁr-
matory tests would need to be run to establish performance parame-
ters, as discussed below, but compared to the high sample volumes
run by these centers it should not be overly burdensome. Of course,
we fully realize that there are many already biobanked samples in
the research system, many of which have been deidentiﬁed and/or
not ideally consented for return of results, and it will therefore not
be possible to apply the above standards to such samples without
considerable expense and effort to re-consent prior participants.
Thus, we are suggesting the above mainly for new patients and re-
search participants.
7. Regulatory considerations
The Federal CLIA statutes clearly state that all phases of testing,
from test submission up to interpretation and reporting procedures,
are subject to oversight by the Centers for Medicare and Medicaid
Services (CMS). Assuming that participation in any one or more of
these testing phases equates to involvement in medical testing then,
practically speaking, if two laboratories agree to split the processesof a medical test, then both should require CLIA accreditation. This
is a point of critical importance, because in the coming years it is like-
ly that economic forces will lead to more whole genome sequencing
being performed in larger centers, at least until sequencing becomes
so inexpensive and ubiquitous that it diffuses back into smaller labs
and even ofﬁce settings. But until then, we are likely to live through
a time when sequencing will be standardized and centralized, and
yet many different downstream clinical analytic processes may be de-
sired. Enacting the type of split described herein allows organizations
to leverage their strengths in sequencing or bioinformatics and lower
costs across the entire process. It may also help spawn a generation of
laboratories devoted to clinical genomic data mining. But if so, it is es-
sential that we as a community think of them and treat them in that
way, as laboratories, even if they may be separated from the wet lab.
Their post-analytic processing would simply be an extension of a
prior wet-lab process, and a core component of a medical test. We
must come to accept the in silico manipulation and mining of DNA in-
formation as not different from its physical manipulation in aqueous
solutions.
If we lose sight of informatics and interpretation as core compo-
nents of medical testing, we will take on huge risk as a community
in the form of unregulated and unsupervised genomic interpretation.
In the clinical genomics ﬁeld, the informatics and interpretation are
the portions of the process most fraught with complexity and that re-
quire the most in-depth knowledge. Every year, sequencing becomes
more straightforward, but analytics and especiallymedical interpretation
are becoming more and more complex. These processes require
strict oversight if the clinical genomics ﬁeld is going to be capable
of maintaining high standards of information and recommendations
for the individuals we serve. CLIA is one available avenue to ensure
on a constant, ongoing basis that these processes are being applied
correctly, by demanding transparency of practices, disclosure of val-
idation data, review of personnel, operating procedures and
patient protection practices, and requiring a system of constant re-
evaluation and improvement.
It is our sense that the various regulatory agencies are realizing
the possibility of additional upcoming test cases for genomics distrib-
utive models and are giving the matter serious thought. From discus-
sions with individuals at CMS and CAP, their view is that in almost all
cases an organization performing post-analytic processes would re-
quire proper CLIA certiﬁcation, but they do not yet have published
guidelines on the matter. CLIA subpart K, section 493.1242 dealing
with specimen submission, handling, and referral, states that a CLIA
certiﬁed lab “must refer a specimen for testing only to [another]
CLIA certiﬁed laboratory or a laboratory meeting equivalent require-
ments as determined by CMS”. While not explicitly covering a split,
this at least offers a framework for inter-lab cooperation. The only
governing body we are aware of that has made a clear statement on
the issue of distributive models is the New York State CLEP program,
which released business practice guidelines in 2008 covering this
model (http://www.wadsworth.org/labcert/clep/Administrative/NYS
BusinessPracticeGuidelines.pdf). CLEP requires both parties in a dis-
tributive model (analytic and interpretive) to be fully licensed, unless
the interpretation is performed by a solo practitioner or small physi-
cian group exclusively for their own patients. The guidelines were
written in this way so as not to infringe on the right of a physician
to practice medicine in the manner they see ﬁt, which is another sig-
niﬁcant though perhaps less important gray area that should be ex-
amined in the future.
8. Practical application and suggested standards
In the largest operating genome sequencing centers in America
(Broad, Baylor, WashU-St. Louis), most, if not all, research exomes
are sequenced to a depth of coverage of 20 reads or more per base
pair in >80% of the target region. In general, the clinical exomes on
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100–150× comparedwith 70–100× for the research exomes. The rea-
son for this emphasis on deeper sequencing for the clinical exomes is
the degree of variability across exome capture baits with respect to
pull-down efﬁcacy. This is common across all exome capture technol-
ogies and results in a skewed depth distribution (Sulonen et al., 2011),
thus requiring high average coverage in order to cover a desired
proportion of the exome at a sufﬁcient depth to make accurate calls.
From a clinical perspective, as depth increases, the sensitivity and
speciﬁcity of variant calls improve dramatically, minimizing unneces-
sary conﬁrmation.
WGS presents a different picture, as sequencing of unselected frag-
ments results in a far more even read depth distribution proﬁle. The
current CLIA-certiﬁed WGS at Illumina is performed with an average
sequencing depth of >30×, with >95% of all calls made at a depth of
greater than 10 reads or more, which is essentially the same as the re-
search gold standard, making the establishment of crossover proce-
dures more straightforward compared with exome sequencing. It
should be noted that the basic Illumina CLIA genome does not include
a conﬁrmation methodology and thus the report recommends sepa-
rate conﬁrmation for concerning ﬁndings prior to patient manage-
ment (Illumina, 2012). Though Illumina is moving towards a full-
process interpreted genome, their original uninterpreted genome is
actually an ideal example of the split model we are advocating for, as
it is essentially a technical product that requires downstream analysis,
interpretation and conﬁrmation in a CLIA-approved setting.Wewould
encourage Illumina to consider expanding this basic CLIA process, cur-
rently a low-volume and higher cost separate sample pathway, and to
move towards making it a standard offering available to both clinical
and research specimens processed in their sequencing core.
The issue of clinical sequencing depth is tricky, particularly
with respect to exomes, because it is difﬁcult to advocate for raising
depth standards across sequencing applications when the sequencing
is already quite expensive. Though there is a ﬁrm rationale for deeper
sequencing for clinical exomes, depending on the application, lower
depth may provide sufﬁcient data for research applications. In the
long term, we believe that the advantages of somewhat higher
depth clinical-grade data would outweigh the associated costs, but
the issue of payers and resources is by no means trivial. Perhaps the
recommendations for split models are best suited for WGS applica-
tions, as the current basic research and clinical standards are quite
similar. Here, for both applications, the largest barrier to higher
depth is cost, and even though 30× average depth is the current
standard, there is a general understanding that this depth opens the
door to signiﬁcant numbers of false positive and negative ﬁndings,
and represents a barrier to sensitive detection of larger structural
rearrangements.
So, in the future it would be desirable for the research and clinical
ﬁeld to move towards higher quality/depth sequencing standards. It
should be noted that these recommendations are not for overnight
adoption. In this ﬁeld, we have seen repeatedly that the impossible
can seem simple with the passage of mere months. Even today, with
the HiSeq 2500, we are capable of performing WGS in just a day or
two for approximately 4–5 thousand dollars. This machine supports
paired reads of 150 bp, 50% higher than HiSeq 2000 reads, and already
certain groups have reported success with dramatically longer read
lengths, which directly produces greater depth. Thus, already this ma-
chine should produce genomes signiﬁcantly in excess of 30×, and as
prices continue to drop, the costs associated with increased depth
will seem more and more reasonable. This is particularly true when
these costs are weighed against the potential beneﬁts, which include
full clinical utility of the primary sequence, better quality data for pro-
jects and resulting databases, reduced prices for clinical sequencing
tests, and reduced costs associated with conﬁrming variants, which
eventually will approach zero as sequencing power and quality im-
proves over time.9. Ethical rationale for more broadly applied clinical sequencing
The topic of analytical variation touches on the critical related eth-
ical issue of return of results, expectations and therapeutic miscon-
ception, about which much has already been written (Zawati and
Knoppers, 2012; Tabor et al., 2011a, 2011b, 2012; Fisher, 2012; Lyon,
2012c; Angrist, 2011, 2013; Lunshof et al., 2010; Angrist and Cook-
Deegan, 2006). Individuals, whether they are well or ill or participat-
ing in a research study, need to be informed during the consent pro-
cess about the exact speciﬁcs of the proposed analysis. This is the
interpretive corollary of the research sequencing dilemma that arises
when clinicians and participants are left uninformed regarding ex-
pected data quality, coverage, and to what degree the data actually
meet those standards. Of course, we fully realize that our society is
rapidly moving toward more and more online activity, with younger
generations more willing to share their data freely among each
other. At some point, we hope that whole genome sequencing will
occur at birth, with all data uploaded to one's own secure proﬁle, to
be used to guide individual health decisions into adulthood and old
age and also as a baseline reference for particular disease states (can-
cer, etc.). This is in linewith the idea that all medical records and infor-
mation should be made available to each respective person. As
recently articulated by Maynard Olson at the Cold Spring Harbor Lab-
oratory Personal Genomes and Medical Genomic conference, such an
arrangement could allow certain people to opt into a “medical infor-
mation donor network”, whereby they would donate their longitudi-
nal phenotype and medical laboratory data, including not only
genomic data but also imaging, blood testing, and many other things.
One can already see that such a thing is possible with the recent move
by the company Facebook to allow people to register themselves as
medical organ donors on their Facebook page (Cohen, 2012). Also,
the Personal Genome Project is helping to break down some of the
fear and mythologies surrounding the public dissemination of geno-
mic data (Ball et al., 2012).
10. Conclusions
NGS-based sequencing has revolutionized howwe pursue genetics
research, and it is starting to produce a similar effect in the clinical ge-
netics space. But it is not just our knowledge, scientiﬁc direction and
expectations for future medical applications that are being trans-
formed. As we move forward, this technology is beginning to push
against our basic historic attitudes regarding what constitutes re-
search vs. medical practice, and is creating a host of resultant ethical
and regulatory dilemmas. Clinical assays are gaining a signiﬁcant dis-
covery component, while our research activities are producing an ex-
plosion of potentially medically relevant data. As a community, it is
essential to explore and intelligently navigate these issues to ensure
a rapid and smooth transition to a time when genomic analysis is a
standard component of individualized care.
Current cost/beneﬁt considerations are largely responsible for im-
peding wider adoption of clinical genome sequencing. Some argue
that the information gleaned for most individuals does not outweigh
the sequencing cost. Merging clinical and research data collection
via a distributive model would help this enormously, as many clinical
patients and research participants have legitimate sequencing needs
and one validated sequencing operation would then producemultiple
beneﬁts. Higher volume clinical-grade genome sequencing would also
drive down clinical sequencing costs, which are currently a 2–3×
multiple of the research costs. Analysis possibilities would then be
left open for any sample: research samples, even if not initially ana-
lyzed for clinical beneﬁt, could be re-processed clinically at any time.
This is a huge potential cost saver, enabling increased clinical utility
to ﬂow from a huge array of genomics projects, along with improved
quality assurance for research samples (Lyon, 2012b; Poste, 2012)
and the elimination of duplicative sequencing. The beneﬁts will
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to the point where base-calling conﬁdence statistics obviate the need
for most conﬁrmatory testing. Improved genomics databases will also
enable more powerful and higher quality future genome interpre-
tation. Therefore, clinical-grade results will enable all information
from a genome/exome to be used for the beneﬁt of the individual, un-
like the current system where many results are not allowed to pass
through the research-clinical wall. All of these beneﬁts will serve to
provide positive feedback and shift the cost/beneﬁt ratio in favor of
further expanded sequencing.
Next-generation sequencing (NGS) is clearly a disruptive technol-
ogy (Christensen, 2003; Christensen et al., 2009; Wu, 2010; Topol,
2012). However, it is important to keep in mind that each of the dis-
ruptive technologies of the past (the automobile, airplane, computer,
etc.) were certainly not free of regulatory or ethical dilemmas at the
time of their introduction, or even to this day, yet each has led to un-
mistakable improvements in our quality of life. This will ultimately
be the case with the genomics revolution, but to realize this promise
we need to plan carefully as a community while remaining cognizant
of ethical and regulatory considerations. We believe that greater reli-
ance on existing CLIA regulations represents the most viable way for-
ward, as CLIA provides clear guidance for ethical issues related to
patient safety and clinical/research demarcation and points us towards
practical and efﬁcient solutions for bringing about true clinical geno-
mics on a large scale.
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